Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study

Stefania Gori; Alessandro Inno; Valentina Rossi; Monica Turazza; Elena Fiorio; Alessandra Fabi; Giancarlo Bisagni; Jennifer Foglietta; Daniele Santini; Ida Pavese; Arianna Pellegrino; A. Zambelli; Patrizia Vici; Vita Leonardi; Sandro Barni; S. Saracchini; Giuseppe Bogina; Fabiana Marchetti; Simona Duranti; Gianluigi Lunardi; Filippo Montemurro

doi:10.1371/journal.pone.0156221

Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study

Stefania Gori, Alessandro Inno, Valentina Rossi, Monica Turazza, Elena Fiorio, Alessandra Fabi, Giancarlo Bisagni, Jennifer Foglietta, Daniele Santini, Ida Pavese, Arianna Pellegrino, A. Zambelli, Patrizia Vici, Vita Leonardi, Sandro Barni, S. Saracchini, Giuseppe Bogina, Fabiana Marchetti, Simona Duranti, Gianluigi LunardiFilippo Montemurro

Research output: Contribution to journal › Article › peer-review

Abstract

Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p

Original language	English
Article number	e0156221
Journal	PLoS One
Volume	11
Issue number	5
DOIs	https://doi.org/10.1371/journal.pone.0156221
Publication status	Published - May 1 2016

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)
Medicine(all)

Access to Document

10.1371/journal.pone.0156221

Fingerprint Dive into the research topics of 'Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study'. Together they form a unique fingerprint.

Cite this

Gori, S., Inno, A., Rossi, V., Turazza, M., Fiorio, E., Fabi, A., Bisagni, G., Foglietta, J., Santini, D., Pavese, I., Pellegrino, A., Zambelli, A., Vici, P., Leonardi, V., Barni, S., Saracchini, S., Bogina, G., Marchetti, F., Duranti, S., ... Montemurro, F. (2016). Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study. PLoS One, 11(5), [e0156221]. https://doi.org/10.1371/journal.pone.0156221

Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer : Results from the italian retrospective multicenter HERLAPAC study. / Gori, Stefania; Inno, Alessandro; Rossi, Valentina; Turazza, Monica; Fiorio, Elena; Fabi, Alessandra ; Bisagni, Giancarlo; Foglietta, Jennifer; Santini, Daniele; Pavese, Ida; Pellegrino, Arianna; Zambelli, A.; Vici, Patrizia; Leonardi, Vita; Barni, Sandro; Saracchini, S.; Bogina, Giuseppe; Marchetti, Fabiana; Duranti, Simona; Lunardi, Gianluigi; Montemurro, Filippo.

In: PLoS One, Vol. 11, No. 5, e0156221, 01.05.2016.

Research output: Contribution to journal › Article › peer-review

Gori, S, Inno, A, Rossi, V, Turazza, M, Fiorio, E, Fabi, A , Bisagni, G, Foglietta, J, Santini, D, Pavese, I, Pellegrino, A, Zambelli, A, Vici, P, Leonardi, V, Barni, S, Saracchini, S, Bogina, G, Marchetti, F, Duranti, S, Lunardi, G & Montemurro, F 2016, 'Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study', PLoS One, vol. 11, no. 5, e0156221. https://doi.org/10.1371/journal.pone.0156221

Gori, Stefania ; Inno, Alessandro ; Rossi, Valentina ; Turazza, Monica ; Fiorio, Elena ; Fabi, Alessandra ; Bisagni, Giancarlo ; Foglietta, Jennifer ; Santini, Daniele ; Pavese, Ida ; Pellegrino, Arianna ; Zambelli, A. ; Vici, Patrizia ; Leonardi, Vita ; Barni, Sandro ; Saracchini, S. ; Bogina, Giuseppe ; Marchetti, Fabiana ; Duranti, Simona ; Lunardi, Gianluigi ; Montemurro, Filippo. / Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer : Results from the italian retrospective multicenter HERLAPAC study. In: PLoS One. 2016 ; Vol. 11, No. 5.

@article{452305de877d474bb0054d9e359187a9,

title = "Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer: Results from the italian retrospective multicenter HERLAPAC study",

abstract = "Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p",

author = "Stefania Gori and Alessandro Inno and Valentina Rossi and Monica Turazza and Elena Fiorio and Alessandra Fabi and Giancarlo Bisagni and Jennifer Foglietta and Daniele Santini and Ida Pavese and Arianna Pellegrino and A. Zambelli and Patrizia Vici and Vita Leonardi and Sandro Barni and S. Saracchini and Giuseppe Bogina and Fabiana Marchetti and Simona Duranti and Gianluigi Lunardi and Filippo Montemurro",

year = "2016",

month = may,

day = "1",

doi = "10.1371/journal.pone.0156221",

language = "English",

volume = "11",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "5",

}

TY - JOUR

T1 - Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer

T2 - Results from the italian retrospective multicenter HERLAPAC study

AU - Gori, Stefania

AU - Inno, Alessandro

AU - Rossi, Valentina

AU - Turazza, Monica

AU - Fiorio, Elena

AU - Fabi, Alessandra

AU - Bisagni, Giancarlo

AU - Foglietta, Jennifer

AU - Santini, Daniele

AU - Pavese, Ida

AU - Pellegrino, Arianna

AU - Zambelli, A.

AU - Vici, Patrizia

AU - Leonardi, Vita

AU - Barni, Sandro

AU - Saracchini, S.

AU - Bogina, Giuseppe

AU - Marchetti, Fabiana

AU - Duranti, Simona

AU - Lunardi, Gianluigi

AU - Montemurro, Filippo

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p

AB - Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p

UR - http://www.scopus.com/inward/record.url?scp=84971450036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971450036&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0156221

DO - 10.1371/journal.pone.0156221

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0156221

ER -